Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial

IMPORTANCE: Administration of gemcitabine-cisplatin, the current standard therapy for advanced biliary tract cancers, results in median progression-free survival and overall survival of 8.0 and 11.7 months, respectively. New treatments offering improved survival outcomes are therefore needed. OBJECT...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JAMA Oncol
Main Authors: Shroff, Rachna T., Javle, Milind M., Xiao, Lianchun, Kaseb, Ahmed O., Varadhachary, Gauri R., Wolff, Robert A., Raghav, Kanwal P. S., Iwasaki, Michiko, Masci, Peter, Ramanathan, Ramesh K., Ahn, Daniel H., Bekaii-Saab, Tanios S., Borad, Mitesh J.
Formato: Artigo
Idioma:Inglês
Publicado: American Medical Association 2019
Assuntos:
Original Investigation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6567834/
https://ncbi.nlm.nih.gov/pubmed/30998813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.0270
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares